I-Mab
NASDAQ:
IMAB
I-Mab is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. I-Mab's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on its unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. I-Mab is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
Pricewaterhousecoopers Zhong Tian LLP
IPO (January 17, 2020)
Cayman Islands
Shanghai, China
Shanghai, HK, US
Jielun Zhu, Internal
86-21-6057-8000
Analyst Coverage
Latest News
September 13, 2021: I-Mab | I-Mab Added to FTSE ESG Index Series (i-mabbiopharma.com)
September 3, 2021: I-Mab | I-Mab Added to FTSE Russell Global Equity Index Series (i-mabbiopharma.com)
September 1, 2021: I-Mab | I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021 (i-mabbiopharma.com)
August 31, 2021: I-Mab | I-Mab Announces Upcoming Participation at September Conferences (i-mabbiopharma.com)
August 19, 2021: I-Mab | I-Mab Announces Establishment of Environmental, Social and Governance Committee (i-mabbiopharma.com)
July 1, 2021: I-Mab | I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio (i-mabbiopharma.com)
June 30, 2021: I-Mab | I-Mab Honored with Top Rankings by Institutional Investor (i-mabbiopharma.com)
June 29, 2021: I-Mab | I-Mab Announces Upcoming Participation at July Conference (i-mabbiopharma.com)
June 25, 2021: I-Mab | I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus (i-mabbiopharma.com)
June 1, 2021: I-Mab | I-Mab Appoints Ruyi He and Rong Shao to Board of Directors (i-mabbiopharma.com)
May 27, 2021: I-Mab | I-Mab Announces Upcoming Participation at June Conferences (i-mabbiopharma.com)
May 19, 2021: I-Mab | I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 (i-mabbiopharma.com)
May 13, 2021: I-Mab | I-Mab Added to MSCI China Index (i-mabbiopharma.com)
April 29, 2021: I-Mab | I-Mab Announces Upcoming Participation at May Conferences (i-mabbiopharma.com)
April 28, 2021: I-Mab | I-Mab Filed 2020 Annual Report on Form 20-F (i-mabbiopharma.com)
April 26, 2021: I-Mab | I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis (i-mabbiopharma.com)
April 14, 2021: I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
March 31, 2021: I-Mab Announces Upcoming Participation at April Conferences
March 29, 2021: I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates
March 24, 2021: I-Mab to Host 2021 R&D Day
March 19, 2021: I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse
March 10, 2021: I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
March 9, 2021: I-Mab’s $177 Million ADSs Follow-on Secondary Offering
March 3, 2021: I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021
February 25, 2021: I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency
February 24, 2021: I-Mab Announces Upcoming Participation at March Conferences
February 10, 2021: I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
February 9, 2021: Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
February 5, 2021: Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Selling Shareholders of I-Mab
February 5, 2021: I-Mab Announces Multiple Clinical Advancements of its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
February 4, 2021: I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
January 25, 2021: I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer